1. Home
  2. INTR vs MLYS Comparison

INTR vs MLYS Comparison

Compare INTR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inter & Co. Inc.

INTR

Inter & Co. Inc.

N/A

Current Price

$5.33

Market Cap

2.3B

Sector

N/A

ML Signal

N/A

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$23.73

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INTR
MLYS
Founded
1994
2019
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
INTR
MLYS
Price
$5.33
$23.73
Analyst Decision
Buy
Strong Buy
Analyst Count
10
10
Target Price
$8.57
★ $48.50
AVG Volume (30 Days)
★ 3.8M
1.2M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
★ 2.12%
N/A
EPS Growth
N/A
★ 37.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$195.44
N/A
P/E Ratio
$16.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.97
$22.30
52 Week High
$10.36
$47.65

Technical Indicators

Market Signals
Indicator
INTR
MLYS
Relative Strength Index (RSI) 48.46 41.01
Support Level $5.22 $22.36
Resistance Level $5.99 $31.19
Average True Range (ATR) 0.18 1.37
MACD -0.02 -0.43
Stochastic Oscillator 56.23 15.65

Price Performance

Historical Comparison
INTR
MLYS

About INTR Inter & Co. Inc.

Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inters mobile application.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: